Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer

BACKGROUND: HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast cancer. The aim of this study was to characterise the pharmacokinetics (PKs) of HuHMFG1 using a population PK model. METHOD: Data were derived from a phase I study of 26 patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: Royer, B, Yin, W, Pegram, M, Ibrahim, N, Villanueva, C, Mir, D, Erlandsson, F, Pivot, X
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833251/
https://www.ncbi.nlm.nih.gov/pubmed/20160731
http://dx.doi.org/10.1038/sj.bjc.6605560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833251/
https://www.ncbi.nlm.nih.gov/pubmed/20160731
http://dx.doi.org/10.1038/sj.bjc.6605560

Ejemplares similares